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Abstracts / Urological Science 26 (2015) S36eS49 S39known. PBNO is a videourodynamic (VUD) diagnosis. The classic presence
of VUD study is high pressure and low ﬂow voiding pattern without
dysfunction of extrinsic sphincter relaxation and distal urethral
obstruction.
Here we presented a 30-year-old male who has difﬁculty voiding. Uro-
ﬂowmetry showed intermittent voiding pattern and low ﬂow rate.
Cystoscopy didn't reveal distal urethral stricture and benign prostatic hy-
perplasia. Videourodynamic study showed high pressure, low ﬂow voiding
pattern. After alpha block medical therapy failed, transurethral bladder
neck incision over 5 and 7 o'clock bidirectional was performed. After
surgery, his urinary ﬂow rate increased. Uroﬂowmetry showed normal
ﬂow pattern with 37 c.c./sec. maximal ﬂow rate. The recovery course was
uneventful and he was satisﬁed with surgical result.
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5-ALPHA-REDUCTASE INHIBITORS AND RISK OF CARDIOVASCULAR
DISEASES
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Purpose: The aim of this study is to investigate the risk of cardiovascular
diseases after 5-alpha-reductase inhibitor (5ARI) therapy for benign
prostate hyperplasia (BPH) using the National Health Insurance Research
Database (NHIRD) in Taiwan.
Materials and methods: In total, 1,486 adult patients newly diagnosed
with BPH andwho used 5-alpha-reductase inhibitors were recruited as the
study cohort, along with 9,995 subjects who did not use 5-alpha-reductase
inhibitors as a comparison cohort. Each patient was monitored for 5 years,
and those who subsequently had cardiovascular diseases were identiﬁed.
A Cox proportional hazards model was used to compare the risk of car-
diovascular diseases between the study and comparison cohorts after
adjusting for possible confounding risk factors.
Results: The patients who received 5ARI therapy had a lower cumulative
rate of cardiovascular diseases than those who did not receive 5ARI therapy
during the 5-year follow-up period (8.4% vs. 11.2%, P ¼ 0.003). In subgroup
analysis, the 5-year cardiovascular event hazard ratio (HR) was lower
among the patients older than 65 years with 91 to 365 cumulative deﬁned
daily dose (cDDD) 5ARI use (HR ¼ 0.63, 95% conﬁdence interval (CI) 0.42 to
0.92; P ¼ 0.018), however there was no difference among the patients with
28 to 90 and more than 365 cDDD 5ARI use (HR ¼ 1.14, 95% CI 0.77 to 1.68;
P ¼ 0.518 and HR ¼ 0.83, 95% CI 0.57 to 1.20; P ¼ 0.310, respectively).
Conclusion: The present study indicated that 5ARI therapy was safe and
did not increase the risk of cardiovascular events in the BPH patients in 5
years of follow-up. Further mechanistic research is needed.
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ASSOCIATION OF PROSTATE BLOOD FLOW WITH MALE LOWER
URINARY TRACT SYMPTOMS
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Hospital, National Cheng Kung University, Tainan, Taiwan
Purpose: To investigate the association of prostate blood ﬂow with lower
urinary tract symptoms in aged male using Doppler spectral waveform
(DSW) analysis.
Materials and methods: We performed a prospective analysis involving
133 aged male patients with clinically imaged benign prostatic hyperpla-
sia. DSW parameters [peak-systolic velocity (PSV), end-diastolic velocity
(EDV), and resistive index (RI)] were measured at bilateral neurovascular
bundle (NVB) vessels and their urethral and capsular branches via Doppler
transrectal ultrasound at the right lateral decubitus position. The associ-
ation of these parameters with lower urinary tract symptoms scred with
international prostate symptom score (IPSS) were analyzed.
Result: Overall, total IPSS scores were signiﬁcantly associated with RI of
each NVB vessels (r2 ¼ 0.03, 0.04; p ¼ 0.04, 0.02, respectively), as well as
PSV of left PSV vessels. PSV of both NVB vessels is associated with the
storage score (p¼ 0.022 and 0.016), rather thanwith the voiding score. Thesummation of frequency and urgency score is also associated with EDV of
bother capsular and urethral branches (p ¼ 0.043 and 0.009, respectively),
as well as PSV of NVB vessels at both sides (p ¼ 0.045 and 0.019,
respectively).
Conclusion: The association of prostate blood ﬂow and lower urinary tract
symptoms exists, mainly with storage symptoms. This ﬁndingmay provide
some information in searching the underlying the etiology.
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PATIENTS WITH BLADDER OUTLET OBSTRUCTION AND DIFFERENT
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Purpose: Bladder outlet obstruction (BOO) may be induced by a wide
range of functional and/or anatomic causes. The resulting obstruction
frequently produces bothersome lower urinary tract symptoms (LUTS) in
patients. The underlying mechanisms responsible for the bladder
dysfunction in BOO remain poorly understood. The purpose of this study is
to investigate the urothelial dysfunction and chronic inﬂammation in pa-
tients with BOO.
Materials and methods: In this prospective study, we enrolled those pa-
tients who presented with LUTS and underwent urodynamic study (VUDS)
for further evaluation. Based on their VUDS performances, it was catego-
rized into 4 sub-groups: control, BOO with detrusor overactivity (DO), BOO
with Detrusor underactivity (DU) and BOO with hypersenstivity bladder
(HSB). Bladder tissues taken from these patients were analyzed. Immu-
noﬂuorescence (IF) staining of junction protein E-cadherin, mast cell,
TUNEL and Zo-1 were performed. The ﬂuorescence intensity of E-cadherin
was measured using an Image J method. The percentage of activated mast
cells and apoptotic cells were measured and quantiﬁed as positive cells per
area unit (4 mm2). The numbers of positive protein were correlate with
VUDS parameters.
Results: A total of 44 men were enrolled in this study. There were 34
patients presented with BOO (DO: 12, DU: 11 and HSB: 11). The expression
and cellular location of E-cadherin, mast cell, TUNEL and Zo-1 were
illustrated in Fig.1. The distribution of E-cadherin is signiﬁcantly reduced in
BOO with DU (8.37 ± 9.50) (p < 0.000), whereas exhibit highest number of
TUNEL (3.60 ± 3.43) (p<0.021). The tryptase signal in BOO with DO is
signiﬁcantly increased (19.05 ± 6.14) (p < 0.000). All these parameters do
not show positive correlation with AbramseGrifﬁths (AG) number.
Increasing number of E-cadherin is associated with Pdet and Qmax.
Tryptase/ mast cell is positively associated with FSF.
Conclusion: In this study, we have shown that LUTS secondary to BOO are
associated with chronic urothelial inﬂammation and urothelial dysfunc-
tion. DU induced by BOO is associated with signiﬁcant urothelial defection.
This may imply that the loss of functional protein and urothelial cell
apoptosis might contribute to the pathophysiology of bladder dysfunction
in BOO.
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Purpose: Since glycosaminoglycans plays an important role in the path-
ophysiology and treatment of interstitial cystitis, we hope to investigate
the potential beneﬁt of small molecular chitosan, which is the monomer of
glycosaminoglycans, in the treatment of cyclophosphamide induced
interstitial cystitis rat model.
Materials and methods: We used cyclophosphamide (CYP) intraperito-
neal injection to induced chronic cystitis in female rats. Treatment with
intravesical chitosan instillation was performed along with cystitis in-
duction. Cystometrogram was performed to evaluate intravesical pressure
and intercontraction interval.
